WallStreetZenWallStreetZen

NASDAQ: RENB
Renovaro Inc Stock

$1.42+0.10 (+7.58%)
Updated May 24, 2024
RENB Price
$1.42
Fair Value Price
N/A
Market Cap
$209.46M
52 Week Low
$0.39
52 Week High
$5.25
P/E
-1.82x
P/B
1.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$53.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.26
Operating Cash Flow
-$11M
Beta
1.08
Next Earnings
Jul 19, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RENB Overview

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RENB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RENB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RENB is good value based on its book value relative to its share price (1.24x), compared to the US Biotechnology industry average (6.08x)
P/B vs Industry Valuation
RENB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RENB due diligence checks available for Premium users.

Be the first to know about important RENB news, forecast changes, insider trades & much more!

RENB News

Valuation

RENB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.82x
Industry
15.58x
Market
32.03x

RENB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.24x
Industry
6.08x
RENB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RENB's financial health

Profit margin

Revenue
$0.0
Net Income
-$17.0M
Profit Margin
0%
RENB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$212.3M
Liabilities
$43.7M
Debt to equity
0.26
RENB's short-term liabilities ($20.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RENB's long-term liabilities ($22.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RENB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RENB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.6M
Investing
-$91.6k
Financing
$2.6M
RENB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RENB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RENB$209.46M+7.58%-1.82x1.24x
CDT$209.68M-4.05%-0.00x-67.66x
ELEV$209.81M+4.07%-3.92x2.77x
GLUE$210.13M+4.26%-1.66x1.38x
HOWL$212.06M-5.43%-4.48x1.80x

Renovaro Stock FAQ

What is Renovaro's quote symbol?

(NASDAQ: RENB) Renovaro trades on the NASDAQ under the ticker symbol RENB. Renovaro stock quotes can also be displayed as NASDAQ: RENB.

If you're new to stock investing, here's how to buy Renovaro stock.

What is the 52 week high and low for Renovaro (NASDAQ: RENB)?

(NASDAQ: RENB) Renovaro's 52-week high was $5.25, and its 52-week low was $0.39. It is currently -72.95% from its 52-week high and 261.32% from its 52-week low.

How much is Renovaro stock worth today?

(NASDAQ: RENB) Renovaro currently has 147,504,944 outstanding shares. With Renovaro stock trading at $1.42 per share, the total value of Renovaro stock (market capitalization) is $209.46M.

Renovaro stock was originally listed at a price of $6.97 in Dec 11, 2018. If you had invested in Renovaro stock at $6.97, your return over the last 5 years would have been -79.61%, for an annualized return of -27.24% (not including any dividends or dividend reinvestments).

How much is Renovaro's stock price per share?

(NASDAQ: RENB) Renovaro stock price per share is $1.42 today (as of May 24, 2024).

What is Renovaro's Market Cap?

(NASDAQ: RENB) Renovaro's market cap is $209.46M, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Renovaro's market cap is calculated by multiplying RENB's current stock price of $1.42 by RENB's total outstanding shares of 147,504,944.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.